Reuters: Replimune's drug for advanced skin cancer fails to win FDA nod again The ​U.S. ‌Food and ​Drug ​Administration ⁠on ​Friday declined ​to approve ​Replimune's ​drug for ‌advanced ⁠skin cancer, ​the ​regulator ⁠said. Replimune's drug for advanced skin cancer fails to win FDA nod again Bloomberg on MSN: Replimune plunges after FDA rejects skin cancer drug again Replimune Group Inc.

Understanding the Context

shares plunged after US regulators rejected the company’s skin cancer treatment for a second time, a sign that they are maintaining their tough stance on drug reviews. People on MSN: Mom, 37, dies of skin cancer after doctors said her mole was 'nothing to worry about' Mom, 37, dies of skin cancer after doctors said her mole was 'nothing to worry about' STAT: Replimune skin cancer drug that became FDA flashpoint is rejected again Yahoo: Skin Cancer 101: A primer on skin cancer and what it might look like Add Yahoo as a preferred source to see more of our stories on Google. Skin cancer is the most common cancer in the U.S., according to the Centers for Disease Control and Prevention. Between 1982 and ...

Key Insights

Skin Cancer 101: A primer on skin cancer and what it might look like European Medical Journal: Skin Cancer Screening Tool Gains Ground in Transplant Care The World Cancer Research Fund notes that skin cancer is the seventeenth most common cancer across the globe. Skin cancer is a global menace, but it might be a greater concern for some than others. Skin cancer is the most common type of cancer, according to the American Cancer Society, and it can be deadly. The American Cancer Society estimates that more than 14,000 people will die from skin ... The best way to detect skin cancer is to know what skin cancer looks like, do monthly self-exams and have regular exams by your health care provider to check for abnormalities that could be cancerous ...

Final Thoughts

A new risk stratification tool for skin cancer in solid organ transplant recipients is gaining global validation. Read more.